Gravity Analytica

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

RLYB 11.26.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-12-04

Name of Upcoming Event:Evercore ISI HealthCONx Conference

Full Press Release SEC Filings Our RLYB Tweets

About Gravity Analytica

Recent Filings

01.06.2025 - 4 Statement of changes in beneficial ownership of securities

PDF Version

NEW HAVEN, Conn.--(BUSINESS WIRE)--Nov. 26, 2024--Rallybio Corporation(Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced thatStephen Uden, M.D., Chief Executive Officer ofRallybio, will participate in a fireside chat at theEvercore ISI HealthCONx ConferenceonWednesday, December 4, 2024at12:30 p.m. ETinCoral Gables, FL.

A live webcast of the fireside chat will be accessible through theEvents and Presentationssection of Rallybio’s website atwww.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.

AboutRallybio

Rallybio(NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases.Rallybiohas built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 inhibitor with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.Rallybiois headquartered inNew Haven, Connecticut. For more information, please visitwww.rallybio.comand follow us onLinkedInandTwitter.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241125485788/en/

Investor ContactsSamantha TracyRallybio Corporation(475) 47-RALLY (Ext. 282)investors@rallybio.comKevin LuiPrecision AQ(212) 698-8691Kevin.Lui@precisionaq.comMediaVictoria ReynoldsMission North(760) 579-2134rallybio@missionnorth.com

Source:Rallybio Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com